 | • レポートコード：MRC2307GR396 • 出版社/出版日：GlobalInfoResearch / 2023年7月 • レポート形態：英語、PDF、105ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥501,120 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,002,240 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界の慢性脳障害治療の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界の慢性脳障害治療市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - 慢性脳障害治療の成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため 慢性脳障害治療市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・作業療法、理学療法、心理療法、言語療法 用途別セグメント ・病院、神経内科診療所 主要な市場プレーヤー ・NeuroVive Pharmaceutical AB、TEVA Pharmaceutical Industries Ltd.、Integra LifeSciences Corporation、Medtronic PLC、Neuren Pharmaceuticals Ltd.、Johnson & Johnson Services Inc.、Smith & Nephew、Stryker、B.Braun Melsungen AG、Neural Analytics, Inc. 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、慢性脳障害治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な慢性脳障害治療メーカーの企業概要、2019年～2022年までの慢性脳障害治療の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な慢性脳障害治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別慢性脳障害治療の販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までの慢性脳障害治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での慢性脳障害治療市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、および慢性脳障害治療の産業チェーンを掲載しています。 ・第14、15章では、慢性脳障害治療の販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - 慢性脳障害治療の概要 - 種類別分析（2018年vs2022年vs2029年）：作業療法、理学療法、心理療法、言語療法 - 用途別分析（2018年vs2022年vs2029年）：病院、神経内科診療所 - 世界の慢性脳障害治療市場規模・予測 - 世界の慢性脳障害治療生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - NeuroVive Pharmaceutical AB、TEVA Pharmaceutical Industries Ltd.、Integra LifeSciences Corporation、Medtronic PLC、Neuren Pharmaceuticals Ltd.、Johnson & Johnson Services Inc.、Smith & Nephew、Stryker、B.Braun Melsungen AG、Neural Analytics, Inc. ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：作業療法、理学療法、心理療法、言語療法 ・用途別分析2018年-2029年：病院、神経内科診療所 ・慢性脳障害治療の北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・慢性脳障害治療のヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・慢性脳障害治療のアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・慢性脳障害治療の南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・慢性脳障害治療の中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Chronic Brain Damage Treatment market size was valued at USD 865.6 million in 2022 and is forecast to a readjusted size of USD 5.2283619933092E+24 million by 2029 with a CAGR of 129195.0% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Chronic Brain Damage is a progressive and fatal brain disease associated with repeated traumatic brain injuries (TBIs), including concussions and repeated blows to the head. It is also associated with the development of dementia. The market for chronic brain damage management includes a range of products and services such as diagnostic tools, therapeutic devices, pharmaceuticals, and rehabilitation services.
This report is a detailed and comprehensive analysis for global Chronic Brain Damage Treatment market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Chronic Brain Damage Treatment market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Chronic Brain Damage Treatment market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Chronic Brain Damage Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Chronic Brain Damage Treatment market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Chronic Brain Damage Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Chronic Brain Damage Treatment market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include NeuroVive Pharmaceutical AB, TEVA Pharmaceutical Industries Ltd., Integra LifeSciences Corporation, Medtronic PLC and Neuren Pharmaceuticals Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Chronic Brain Damage Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Occupational therapy
Physical therapy
Psychotherapy
Speech or language therapy
Market segment by Application
Hospitals
Neurology Clinics
Major players covered
NeuroVive Pharmaceutical AB
TEVA Pharmaceutical Industries Ltd.
Integra LifeSciences Corporation
Medtronic PLC
Neuren Pharmaceuticals Ltd.
Johnson & Johnson Services Inc.
Smith & Nephew
Stryker
B.Braun Melsungen AG
Neural Analytics, Inc.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Chronic Brain Damage Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Chronic Brain Damage Treatment, with price, sales, revenue and global market share of Chronic Brain Damage Treatment from 2018 to 2023.
Chapter 3, the Chronic Brain Damage Treatment competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Chronic Brain Damage Treatment breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Chronic Brain Damage Treatment market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Chronic Brain Damage Treatment.
Chapter 14 and 15, to describe Chronic Brain Damage Treatment sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Chronic Brain Damage Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Chronic Brain Damage Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Occupational therapy
1.3.3 Physical therapy
1.3.4 Psychotherapy
1.3.5 Speech or language therapy
1.4 Market Analysis by Application
1.4.1 Overview: Global Chronic Brain Damage Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Neurology Clinics
1.5 Global Chronic Brain Damage Treatment Market Size & Forecast
1.5.1 Global Chronic Brain Damage Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Chronic Brain Damage Treatment Sales Quantity (2018-2029)
1.5.3 Global Chronic Brain Damage Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 NeuroVive Pharmaceutical AB
2.1.1 NeuroVive Pharmaceutical AB Details
2.1.2 NeuroVive Pharmaceutical AB Major Business
2.1.3 NeuroVive Pharmaceutical AB Chronic Brain Damage Treatment Product and Services
2.1.4 NeuroVive Pharmaceutical AB Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 NeuroVive Pharmaceutical AB Recent Developments/Updates
2.2 TEVA Pharmaceutical Industries Ltd.
2.2.1 TEVA Pharmaceutical Industries Ltd. Details
2.2.2 TEVA Pharmaceutical Industries Ltd. Major Business
2.2.3 TEVA Pharmaceutical Industries Ltd. Chronic Brain Damage Treatment Product and Services
2.2.4 TEVA Pharmaceutical Industries Ltd. Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 TEVA Pharmaceutical Industries Ltd. Recent Developments/Updates
2.3 Integra LifeSciences Corporation
2.3.1 Integra LifeSciences Corporation Details
2.3.2 Integra LifeSciences Corporation Major Business
2.3.3 Integra LifeSciences Corporation Chronic Brain Damage Treatment Product and Services
2.3.4 Integra LifeSciences Corporation Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Integra LifeSciences Corporation Recent Developments/Updates
2.4 Medtronic PLC
2.4.1 Medtronic PLC Details
2.4.2 Medtronic PLC Major Business
2.4.3 Medtronic PLC Chronic Brain Damage Treatment Product and Services
2.4.4 Medtronic PLC Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Medtronic PLC Recent Developments/Updates
2.5 Neuren Pharmaceuticals Ltd.
2.5.1 Neuren Pharmaceuticals Ltd. Details
2.5.2 Neuren Pharmaceuticals Ltd. Major Business
2.5.3 Neuren Pharmaceuticals Ltd. Chronic Brain Damage Treatment Product and Services
2.5.4 Neuren Pharmaceuticals Ltd. Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Neuren Pharmaceuticals Ltd. Recent Developments/Updates
2.6 Johnson & Johnson Services Inc.
2.6.1 Johnson & Johnson Services Inc. Details
2.6.2 Johnson & Johnson Services Inc. Major Business
2.6.3 Johnson & Johnson Services Inc. Chronic Brain Damage Treatment Product and Services
2.6.4 Johnson & Johnson Services Inc. Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Johnson & Johnson Services Inc. Recent Developments/Updates
2.7 Smith & Nephew
2.7.1 Smith & Nephew Details
2.7.2 Smith & Nephew Major Business
2.7.3 Smith & Nephew Chronic Brain Damage Treatment Product and Services
2.7.4 Smith & Nephew Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Smith & Nephew Recent Developments/Updates
2.8 Stryker
2.8.1 Stryker Details
2.8.2 Stryker Major Business
2.8.3 Stryker Chronic Brain Damage Treatment Product and Services
2.8.4 Stryker Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Stryker Recent Developments/Updates
2.9 B.Braun Melsungen AG
2.9.1 B.Braun Melsungen AG Details
2.9.2 B.Braun Melsungen AG Major Business
2.9.3 B.Braun Melsungen AG Chronic Brain Damage Treatment Product and Services
2.9.4 B.Braun Melsungen AG Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 B.Braun Melsungen AG Recent Developments/Updates
2.10 Neural Analytics, Inc.
2.10.1 Neural Analytics, Inc. Details
2.10.2 Neural Analytics, Inc. Major Business
2.10.3 Neural Analytics, Inc. Chronic Brain Damage Treatment Product and Services
2.10.4 Neural Analytics, Inc. Chronic Brain Damage Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Neural Analytics, Inc. Recent Developments/Updates
3 Competitive Environment: Chronic Brain Damage Treatment by Manufacturer
3.1 Global Chronic Brain Damage Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Chronic Brain Damage Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Chronic Brain Damage Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Chronic Brain Damage Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Chronic Brain Damage Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Chronic Brain Damage Treatment Manufacturer Market Share in 2022
3.5 Chronic Brain Damage Treatment Market: Overall Company Footprint Analysis
3.5.1 Chronic Brain Damage Treatment Market: Region Footprint
3.5.2 Chronic Brain Damage Treatment Market: Company Product Type Footprint
3.5.3 Chronic Brain Damage Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Chronic Brain Damage Treatment Market Size by Region
4.1.1 Global Chronic Brain Damage Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Chronic Brain Damage Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Chronic Brain Damage Treatment Average Price by Region (2018-2029)
4.2 North America Chronic Brain Damage Treatment Consumption Value (2018-2029)
4.3 Europe Chronic Brain Damage Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Chronic Brain Damage Treatment Consumption Value (2018-2029)
4.5 South America Chronic Brain Damage Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Chronic Brain Damage Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Chronic Brain Damage Treatment Sales Quantity by Type (2018-2029)
5.2 Global Chronic Brain Damage Treatment Consumption Value by Type (2018-2029)
5.3 Global Chronic Brain Damage Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Chronic Brain Damage Treatment Sales Quantity by Application (2018-2029)
6.2 Global Chronic Brain Damage Treatment Consumption Value by Application (2018-2029)
6.3 Global Chronic Brain Damage Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Chronic Brain Damage Treatment Sales Quantity by Type (2018-2029)
7.2 North America Chronic Brain Damage Treatment Sales Quantity by Application (2018-2029)
7.3 North America Chronic Brain Damage Treatment Market Size by Country
7.3.1 North America Chronic Brain Damage Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Chronic Brain Damage Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Chronic Brain Damage Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Chronic Brain Damage Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Chronic Brain Damage Treatment Market Size by Country
8.3.1 Europe Chronic Brain Damage Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Chronic Brain Damage Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Chronic Brain Damage Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Chronic Brain Damage Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Chronic Brain Damage Treatment Market Size by Region
9.3.1 Asia-Pacific Chronic Brain Damage Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Chronic Brain Damage Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Chronic Brain Damage Treatment Sales Quantity by Type (2018-2029)
10.2 South America Chronic Brain Damage Treatment Sales Quantity by Application (2018-2029)
10.3 South America Chronic Brain Damage Treatment Market Size by Country
10.3.1 South America Chronic Brain Damage Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Chronic Brain Damage Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Chronic Brain Damage Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Chronic Brain Damage Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Chronic Brain Damage Treatment Market Size by Country
11.3.1 Middle East & Africa Chronic Brain Damage Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Chronic Brain Damage Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Chronic Brain Damage Treatment Market Drivers
12.2 Chronic Brain Damage Treatment Market Restraints
12.3 Chronic Brain Damage Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Chronic Brain Damage Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Chronic Brain Damage Treatment
13.3 Chronic Brain Damage Treatment Production Process
13.4 Chronic Brain Damage Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Chronic Brain Damage Treatment Typical Distributors
14.3 Chronic Brain Damage Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
• 日本語訳：慢性脳障害治療の世界市場2023：作業療法、理学療法、心理療法、言語療法
• レポートコード：MRC2307GR396 ▷ お問い合わせ（見積依頼・ご注文・質問）